Acute Promyelocytic Leukemia

Trisenox patent exclusivity extended from 2007 to late 2018

Published in Medical Letter on the CDC and FDA, February 29th, 2004

Cell Therapeutics, Inc., (CTI) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application that, when issued, includes coverage directed to CTI's drug Trisenox (arsenic trioxide) injection.

CTI has an exclusive license to this patent property. Upon issuance, the U.S. patent will extend CTI's U.S. intellectual property position for Trisenox 11 years beyond the original orphan drug designation that currently expires in 2007.

The resulting patent will allow CTI to invest in label expansion studies in additional diseases, which could add significantly to the annual sales growth of the product. CTI markets...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-02-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry